Kornimate/medical-research-clean huggingface dataset:
clinical evaluation of the fracture resistance for e-max cad and vita suprinity laminate veneers

Conditions: Tooth Discoloration

Summary: patients need laminate veneer for their teeth usually use emax cad as an etchable ceramic. yet fracture may occur so a stronger material is needed. vita suprinity is a recent material with glass ceramic enriched with zirconia (approx. 10% by weight) that offer practices and laboratories a high-strength, zirconia-reinforced lithium silicate ceramic (zls) and can be used to fabricate laminate veneers but the investigators have to know clinically it is fracture resistance, so the investigators are going to have parallel groups in a randomized clinical trial.


Eligibility criteria:
inclusion criteria: all subjects are required to be: * from 18-60 years old, and able to read and sign the informed consent document. * physically and psychologically able to tolerate conventional restorative procedures * have no active periodontal or pulpal diseases, have teeth with good restorations * patients with teeth problems indicated for laminate veneer (e.g. discoloration, fracture not involve more than 50% enamel loss, mild malposition, ....) * willing to return for follow-up examinations and evaluation exclusion criteria: * patients in the growth stage with partially erupted teeth * patient with fractured teeth of more than 50% enamel loss * patients with poor oral hygiene and motivation * pregnant women * psychiatric problems or unrealistic expectations * lack of opposite occluding dentition in the area intended for restoration
patient satisfaction with different numbers of implants

Conditions: Patient Satisfaction

Summary: the goal of this randomized controlled trial aimed to assess patient satisfaction for completely edentulous patients with implant overdenture retained by ball attachment over a single symphyseal , or four interforaminal implants when compared to two interforaminal ones

48 edentulous patients were recruited and randomized to receive either 1,2 or 4 implants for a mandibular overdenture,3 months later implants were uncovered, and ball attachments were torqued, and all overdentures were picked up ,patient satisfaction questionnaires were recorded for all patients 2 weeks after pickup 3 months ,6 months, 9 months and 1year.

Eligibility criteria:
inclusion criteria * completely edentulous patients with restorative space of 12-15 mm, * keratinized gingiva of 5 mm exclusion criteria * exclusion criteria: * uncontrolled diabetes * bruxers * smokers
carboplatin and temozolomide (temodar) for recurrent and symptomatic residual brain metastases

Conditions: Brain Tumor; Brain Metastases

Summary: purpose: the primary objective of this study is to determine if chemotherapy with carboplatin and temozolomide significantly affects the response rates, or size of disease, in patients with brain metastases, originating from cancer in other parts of the body, compared to patients who have already been treated with radiation. survival, causes of death, recurrence of disease in the central nervous system, toxicity, and quality of life will all be measured as secondary objective in this study.

rationale: surgery and radiation are often used as treatments for brain metastases, or tumors in the brain that originate from other parts of the body. it is currently unknown whether patient survival or time to progression would experience additional benefits through the addition of chemotherapy. previous research does appear to suggest that a chemotherapy regimen may improve outcomes of patients with brain metastases previously treated with radiation. the current study further evaluates this research question by providing patients with recurrent or symptomatic residual brain metastases with carboplatin and temozolomide, two chemotherapy agents. temozolomide has demonstrated clinical antitumor efficacy against malignant gliomas and has been tested with some efficacy against several other types of cancer. this drug appears to have less adverse effects compared to other commonly used cancer drugs. recent research indicates that temozolomide also has some efficacy against brain metastases. in addition, previous research indicates carboplatin's lack of severe toxicity in patients with this disease. treatment: study participants will be treated with carboplatin and temozolomide. carboplatin will be administered through intravenous infusions. temozolomide will be given through oral pills. before these drugs are administered, study participants will undergo a pre-treatment evaluation with physical and neuropsychological examinations, neuro-imaging, laboratory tests, quality of life assessment, and other procedures. carboplatin will be given for two consecutive days. temozolomide will be taken by study participants daily for five consecutive days. both of these treatment schedules will be repeated every 28 days. several tests and exams will be given throughout the study to closely monitor patients. study treatments will be discontinued due to disease growth or unacceptable adverse events.

Eligibility criteria:
inclusion criteria: * pathologically confirmed systemic cancer exclusion criteria: * pregnant * known cns meningeal involvement with cancer

Keywords: recurrent symptomatic
projected prognosis as a predictor of short-term outcome after treatment of minor musculoskeletal injuries in the emergency department

Conditions: Musculoskeletal Diseases

Summary: this study describes the caseload treated by the extended scope physiotherapists(esp) working in the emergency department at slagelse hospital. patients treated by the esp during a 3 month period will be included in this study. furthermore we aim to assess if esps treating patients with minor musculoskeletal injuries in the ed can predict the short-term prognosis of recovery. the prediction is made at hospital discharge using a (-7/+7) numerical rating scale (-7=poor prognosis; 7=best prognosis).


Eligibility criteria:
inclusion criteria: * 1 treated by an esp for a minor musculoskeletal injury in the emergency room * 2 has an email address * 3 signed informed consent form exclusion criteria: * 1 a condition that, in the opinion of the investigator, would preclude participation in the study (e.g., not having access to the internet, cognitive impairments etc.) * 2 under the influence of drugs or alcohol

Keywords: minor musculoskeletal injuries emergency department prediction outcome extended scope physiotherapists
avatar intervention for the treatment of cannabis use disorder in patients with severe mental health disorders

Conditions: Psychotic Disorders; Cannabis Use Disorder; Mental Health Disorder

Summary: this is a proof-of-concept of a new virtual reality (vr) avatar intervention for cannabis use disorders (cud) in patients with psychotic disorders and/or mood disorders. the primary outcomes are reductions in cannabis use, cannabis use disorder severity, and increased quality of life.

cannabis use disorder (cud) is a complex issue, even more so when it is comorbid with a psychotic disorder or a mood disorder. indeed, this population seems more vulnerable to this substance since the incidence of developing cud is five to six times higher compared to the general population. in these populations, cannabis use is one of the key factors leading to psychiatric re-hospitalization. it is associated with depressive symptoms, medication non-compliance, hostility, as well as reduced quality of life. unfortunately, there is no evidence-based intervention available for the treatment of cud in this population. novel interventions for cud are thus critically needed. virtual reality-based therapies are a promising avenue that allow patients to try novel strategies in real time instead of having to learn abstract concepts. in response to this clinical need, our team has created a distinctive intervention for cud in patients with psychotic disorders and/or mood disorders. the avatar intervention displays strong experiential and relational components that are crucially missing in conventional interventions. this proposal thus aims to conduct a proof-of-concept to assess the efficacity of avatar intervention for cud in patients with psychotic disorders and/or mood disorders. the primary objective of this open trial will be to determine whether cannabis-related outcomes (i.e. frequency and quantity of use) diminish after treatment as well as 3- 6- and 12-months follow-up. as for secondary objectives, the investigator will seek to determine the effect of the intervention on motivation to change, severity of cannabis dependence, psychiatric symptoms (mood and psychotic) and whether quality of life improves after treatment, at 3- 6- and 12-months follow-up. as there is no evidence-based therapeutic options for cud in patients with psychotic disorders and/or mood disorders, the current trial will contribute to the validation of a novel approach and create new therapeutic possibilities.

Eligibility criteria:
inclusion criteria: * males or females over 18 years of age who meet the dsm-5 criteria for cud (≥4 criteria) ; * patients will meet the dsm-5 criteria for schizophrenia, schizoaffective disorder, bipolar disorder and major depression. diagnoses will be established with the structured interview for dsm-5 (scid-5). exclusion criteria: * ongoing pharmacological or psychological treatment for cud ; * ongoing detoxification for cannabis withdrawal ; * presence of neurological disorders ; * presence of a severe and unstable physical illness ; * inability to provide consent.

Keywords: cannabis virtual reality intervention psychotic disorders substance use disorders
end-expiratory trans-pulmonary pressure guided peep titration in patients with pulmonary fibrosis and uip pattern undergoing mechanical ventilation

Conditions: Idiopathic Pulmonary Fibrosis; Mechanical Ventilation Pressure High

Summary: patients with pulmonary fibrosis and associated usual interstitial pneumonia that require mechanical ventilation for acute respiratory failure experience poor clinical outcomes. this may be influenced by the unfavorable interaction between the fibrotic lung and the stress and strain stimuli generated during controlled ventilation. although there is no consensus on how to ventilate these patients, much of the recommendations followed in clinical practice are taken from the experience on patients with acute respiratory distress syndrome. among these, measuring the esophageal pressures and adjusting positive-end expiatory pressure to make trans-pulmonary pressures positive can decrease atelectasis, derecruitment of lung, and cyclical opening and closing of airways and alveoli, thus optimizing lung mechanics and oxygenation. the effect of this strategy on the fibrotic lung has not yet been documented. with this observational study we aim at documenting the effect of peep titration maneuver based on end-expiratory trans-pulmonary pressure on lung mechanics of patients with pulmonary fibrosis and uip pattern,


Eligibility criteria:
inclusion criteria: * pulmonary fibrosis with uip pattern * subjected to endotracheal intubation and controlled mechanical ventilation for acute respiratory failure * candidate to a trial of peep titration according to positive end expiratory pressure. exclusion criteria: * chest wall deformities * chronic obstructive pulmonary disease
caffeine citrate use and electronic activity of the diaphragm (edi) changes

Conditions: Preterm; Apnea of Prematurity; Caffeine

Summary: caffeine citrate, the first-line agent for apnea of prematurity, enhances diaphragmatic activity. edi values of neurally adjusted ventilatory assist (nava) modes can be used to quantify the diaphragmatic activity triggered by electrical impulse from the respiratory center. this study aims to evaluate the edi changes following caffeine citrate administration and cessation in preterm infants, and whether such changes are affected by different doses used variably in clinical settings.

caffeine citrate has been used as the first-line agent for apnea of prematurity. it works via mechanisms including stimulation of the respiratory center in medulla, increasing sensitivity to carbon dioxide retention, and increment in diaphragmatic activity. the effect of caffeine citrate has been evaluated largely based on parameters concerning clinical symptoms (e.g., decrease in the number of apnea, extubation success, decreased incidence of bronchopulmonary dysplasia) but not quantified parameters of actual diaphragmatic activity. also, while usual doses of caffeine administration is described in the literature, consensus on the effect of caffeine citrate depending on different dosages has not been established. the current study aims to evaluate effect of caffeine citrate by quantifying the electrical impulses of diaphragmatic activity using edi values captured from neurally adjusted ventilatory assist (nava) mode. out of preterm infants necessitating invasive or non-invasive ventilators, those who are supported by invasive or non-invasive nava would be recruited. edi changes would be monitored for the following timepoints: at the administration of caffeine citrate loading dose, 1st maintenance dose after loading, and at cessation of caffeine citrate.

Eligibility criteria:
inclusion criteria: * preterm infants born at less than 34 weeks' gestation who are supported by invasive or non-invasive nava exclusion criteria: * major congenital anomaly, chromosomal or genetic abnormality
a phase 1 clinical trial to investigate pharmacokinetics and drug interaction of crestor and glucodown or sr in healthy volunteers

Conditions: Pharmacokinetics and Drug Interaction of Crestor and Glucodown SR

Summary: this clinical trial is designed to compare the pharmacokinetic characteristics of combination and separate administration of crestor(rosuvastatin) and glucodown(metformin sr). also investigate drug interaction between separate and combination administration. total number of subjects is 36. 6 group(6 for 1 group), 3 period, consecutive 5 day administration, 10 days washout after 5th day of administration. all subjects take crestor alone, glucodown alone, crestor+glucodown combination during 3 each period.


Eligibility criteria:
inclusion criteria: * 20\~50 yrs old, healthy korean subjects * body weight \<ideal body weight±20% * no congenital, chronic disease, no current disease * subjects who are diagnosed to include by medical doctor from laboratory and ecg result. * subjects who agree to keep contraceptive methods during the clinical trial. exclusion criteria: * subjects who are allergic to investigational drug. * subjects who have a medical history which can affect the clinical trial. * hypertension(systolic bp ≥ 150mmhg or diastolic bp ≥ 100mmhg), hypotension(systolic bp ≤ 100mmhg or diastolic bp ≤ 65mmhg) * subjects who have taken other medicine in recent 2\~4 weeks. * subjects who have a risk of hypoglycemia and imbalance in taking a diet.

Keywords: drug interaction rosuvastatin metformin sr pharmacokinetic
intranasal versus intravenous ketamine for procedural sedation in children with non-operative fractures

Conditions: Trauma; Fractures, Closed; Children, Only; Deep Sedation; Ketamine

Summary: this a randomized clinical trial involving children with non-operative fractures presenting the emergency department randomized either to intranasal or intravenous ketamine.

the purpose of this study is to determine if intranasal ketamine (ink) is efficacious for procedural sedation and analgesia (psa) when compared to intravenous ketamine (ivk) in children with non-operative fractures. the primary aim is to determine if ink provides non-inferior sedation to ivk as defined by a modified ramsay sedation score of ≥ 4 and also to compare the proportion of successful procedure between two treatment groups. the secondary aim is to compare proportion of adverse events and compare duration of sedation and length of emergency department (ed) stay between treatment groups.

Eligibility criteria:
inclusion criteria: * children 1-18 years of age. * american society of anesthesiologists (asa) i or ii * non-operative fracture requiring reduction * body weight less than or equal to 25 kg as measured by standard weighing scale exclusion criteria: * asa classification iii or above * age less than 1 year * history of hypertension, known coronary artery disease or kawasaki disease, congestive heart failure, acute glaucoma or globe injury, increased intracranial pressure or intracranial mass lesion, acute porphyria, developmental delays, or major psychiatric disorder * prior allergy to ketamine * unavailable parent or guardian to provide consent * non-english speaking

Keywords: procedural sedation ketamine pediatric fracture intranasal intravenous emergency department
study to evaluate the safety of 1 new 6:2 influenza virus reassortant in adults for the 2016-2017 season

Conditions: Influenza; Healthy

Summary: this prospective annual release study is designed to evaluate the safety of 1 new influenza virus vaccine strain to be included in flumist quadrivalent for the 2016-2017 influenza season

this prospective, randomized, double-blind, placebo-controlled release study will enroll approximately 300 healthy adults 18 to 49 years of age. eligible subjects will be randomly assigned in a 4:1 fashion to receive a single dose of monovalent vaccine or placebo by intranasal spray. randomization will be stratified by site. this study will be conducted at 3 sites in the united states of america. each subject will receive 1 dose of investigational product on day 1. the duration of study participation for each subject is the time from study vaccination through 180 days after study vaccination.

Eligibility criteria:
inclusion criteria: * age 18 through 49 years * written informed consent * subject available by telephone * ability to understand and comply with the requirements of the protocol, as judged by the investigator exclusion criteria: * concurrent enrollment in another clinical study up to 180 days after receipt of investigational product (day 181) * history of hypersensitivity to any component of the vaccine, including egg or egg protein or serious, life threatening, or severe reactions to previous influenza vaccinations * any condition for which the inactivated influenza vaccine is indicated, including chronic disorders of the pulmonary or cardiovascular systems (example \[eg\], asthma), chronic metabolic diseases (eg, diabetes mellitus), renal dysfunction, or hemoglobinopathies that required regular medical follow-up or hospitalization during the preceding year * acute febrile (greater than \[\>\] 100.0 degrees fahrenheit \[f\] oral or equivalent) and/or clinically significant respiratory illness (example, cough or sore throat) within 14 days prior to randomization * any known immunosuppressive condition or immune deficiency disease, including human immunodeficiency virus infection, or ongoing immunosuppressive therapy * history of guillain-barré syndrome

Keywords: trivalent influenza flumist quadrivalent vaccine prevention healthy monovalent
a prospective, randomized study comparing cemented and cementless total knee replacement

Conditions: Knee Osteoarthritis

Summary: the purpose of this study is to compare the the nexgen knee replacement system using cementless fixation with the same system using cemented fixation. at minimum 2-year follow-up, the hypothesis is that nexgen total knee arthroplasties using cementless and cemented fixation will demonstrate no differences in clinical outcome based on oxford and knee society scores, patient-assessed visual analog pain, clinical complications, radiographic fixation and implant survivorship.


Eligibility criteria:
inclusion criteria: * primary diagnosis of osteoarthritis of the knee * patients undergoing primary total knee replacement exclusion criteria: * age over 75 years old * prior unicondylar knee arthroplasty * grossly porotic bone or bone defects requiring bone grafting * bone cuts not sufficiently accurate for cementless fixation

Keywords: total knee arthroplasty total knee replacement cementless tka high flexion trabecular metal
a retrospective, observational, noninterventional data collection study for patients with molybdenum cofactor deficiency who have been previously treated with cyclic pyranopterin monophosphate (cpmp)

Conditions: Molybdenum Cofactor Deficiency

Summary: the primary objective is to assess safety and efficacy data of escherichia coli-derived cpmp in patients with molybdenum cofactor deficiency (mocd).


Eligibility criteria:
inclusion criteria: 1. male or female of any age. 2. patient with mocd type a, suspected type a, or type b. 3. patient previously received cpmp only by intravenous route of administration. 4. parent(s) or legal guardian(s), depending on local regulations, has voluntarily provided written informed consent for the investigator, investigator's designee, or sponsor designee to review, collect, transmit, and analyze data extracted from the medical record. in the case of a deceased patient for whom the parents or legal guardians could not be located, the appropriate ethical review committee may assign another person as legal representative to provide consent, where applicable per local and country regulations. exclusion criteria: * patient's parent(s) or legal guardian(s) are unable to understand the nature and scope of the study.
robot-assisted gait therapy in the subacute phase of first ischemic stroke

Conditions: Ischemic Stroke

Summary: robot-assisted gait training (ragt) represents a modern concept of neurorehabilitation in stroke patients. this single-center randomized parallel-group neurorehabilitation trial with blinded primary outcome assessment is aimed at patients after the first-ever ischaemic stroke in the anterior or posterior cerebral circulation.

the main aim is to determine, whether the ragt by using the lokomat exoskeleton device (hoccoma, switzerland) plus the protocol-defined conventional rehabilitation versus conventional rehabilitation improves the gait of post-stroke patients after 6 months. both groups are treated with the protocol-defined rehabilitation (ergotherapy and physiotherapy) for 60 min 5 times a week, a total of 15 times within 3 weeks (a total of 1200 min). the lokowalkers group undergoes the ragt using the lokomat pro freed device for 20-50 minutes 5 times a week for a total of 15 times for 3 weeks (a total of 1800 minutes). the primary endpoint is the functional ambulation category (fac) after 3 months. secondary endpoints include fac (after 15th therapy), 10-meter walk test (10mwt) (after 15th therapy, after 3 months), timed up and go test (tug) (after 15th therapy and after 3 months, 3-months modified rankin scale (mrs), and berg balance scale (bbs, after 15th therapy, after 3 months).

Eligibility criteria:
inclusion criteria: * signed informed consent by the participant or legal representative * interval between stroke and first rehabilitation session \< 6 weeks (study target within 2 weeks) * age \> 18 years * early modified rankin scale (mrs) 2 to 4 (pre-stroke mrs 0 to 1) * early fac of 0 to 3 (pre-stroke fac of 5) * standing ability with support up to 3 minutes and vertical tolerance \> 15 minutes exclusion criteria: * inability or refusal to sign an informed consent * history of stroke or another brain disease (tumour, multiple sclerosis, brain or spinal cord injury) * severe internal, oncological, or surgical comorbidity preventing long-term re-habilitation or causing chronic or progressive gait disorder * limited collaboration of any reason, moderate or severe dementia assessed by using the montreal cognitive assessment (moca) scale * impaired skin integrity in the lower torso and limbs preventing the use of lokomat device * limitations given by the lokomat exoskeleton device (weight \> 135 kg, thigh-length 23-35 cm, shank length 35-47cm) * limitations given by the leg/lower body exerciser (weight \> 180 kg, height \ 200 cm, (sub)acute lower limb fractures, deep vein thrombosis, skin disintegration) * any contraindication to perform brain mri

Keywords: gait stroke robotic rehabilitation exoskeleton neurorehabilitation lokomat